Novartis AG is considering a sale of its dermatology generics drugs business and the unit could be valued at between $1 billion to $1.5 billion, Bloomberg said. The assets for sale include skin-care treatments and some manufacturing facilities, the story said. Private equity and other drug makers are expected to be interested, the report said.
Source: https://www.pehub.com/2017/11/novartis-considers-sale-of-generics-drug-business-bloomberg/
Powered by WPeMatico
Comments are closed.